A Phase 2 Clinical Study of ABSK061 and ABSK043
A phase 2 trial of ABSK061, CAPOX in non-small-cell lung cancer and small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.
Overview
A Phase 2 Clinical Study of ABSK061 and ABSK043 is a phase 2 interventional study registered as NCT06632262 by Abbisko Therapeutics Co, Ltd, with 202 participants planned, started 2024-11-13 and due to reach its primary completion in 2029-11-30. Interventions recorded: ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX. Conditions listed: HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors. No results are recorded here; the registry entry is the source.
Setting
An Open-label Phase 2, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Efficacy of ABSK061 and ABSK043 with or Without Chemotherapy in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
Phase
Phase 2
Sponsor
Abbisko Therapeutics Co, Ltd
Registry
Enrolled
202